The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Can novel immunotherapies cure multiple myeloma?
Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on the current and emerging treatments for multiple myeloma discussed at ASH 2020. Immunomodulatory therapies such as bispecific T-cell engagers (BiTEs) and CAR T-cells are showing deep and durable responses, even among relapsed/refractory patients. While immunomodulatory drug and proteasome inhibitor combinations and transplants are still the standard of care, the future may see sequential use of immunotherapies to restore a memory immune response against myeloma, which may have curative potential. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
